deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 4-arm NCT01033552

Biochemical Correction of Severe EB by Allo HSCT and Off-the-shelf MSCs

MT2009-09: Biochemical Correction of Severe Epidermolysis Bullosa by Allogeneic Stem Cell Transplantation and Off-the-shelf Mesenchymal Stem Cells

Sponsor: Masonic Cancer Center, University of Minnesota

Conditions Epidermolysis Bullosa
Interventions Anti-thymocyte globulin Bone marrow or umbilical cord blood (UCG) stem cell transplantation Cyclophosphamide Fludarabine Mesenchymal stem cell transplantation Myeloablative Busulfan Total body irradiation
Updated 17 times since 2017 Last updated: Mar 6, 2024 Started: Jan 31, 2010 Primary completion: Aug 12, 2021 Completion: Aug 12, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Epidermolysis Bullosa, this trial is completed. The trial is conducted by Masonic Cancer Center, University of Minnesota and has accumulated 17 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Dec 2017 · 7 months · monthly snapshot~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshot~Oct 2018 – ~Oct 2019 · 12 months · monthly snapshot~Oct 2019 – ~Dec 2019 · 2 months · monthly snapshot~Dec 2019 – ~Dec 2020 · 12 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Jun 2021 · 5 months · monthly snapshot~Jun 2021 – ~Apr 2022 · 10 months · monthly snapshot~Apr 2022 – ~Oct 2022 · 6 months · monthly snapshot~Oct 2022 – ~Mar 2023 · 5 months · monthly snapshot~Mar 2023 – ~May 2024 · 14 months · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. May 2024 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  4. Mar 2023 — May 2024 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not Recruiting → Completed

  5. Oct 2022 — Mar 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

▶ Show 12 earlier versions

  1. Apr 2022 — Oct 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting · Phase: PHASE2 → PHASE1_PHASE2

  2. Jun 2021 — Apr 2022 [monthly]

    Recruiting PHASE2

  3. Jan 2021 — Jun 2021 [monthly]

    Recruiting PHASE2

  4. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  5. Dec 2019 — Dec 2020 [monthly]

    Recruiting PHASE2

  6. Oct 2019 — Dec 2019 [monthly]

    Recruiting PHASE2

  7. Oct 2018 — Oct 2019 [monthly]

    Recruiting PHASE2

  8. Jun 2018 — Oct 2018 [monthly]

    Recruiting PHASE2

  9. Dec 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

  10. May 2017 — Dec 2017 [monthly]

    Recruiting PHASE2

  11. Feb 2017 — May 2017 [monthly]

    Recruiting PHASE2

  12. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Jan 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Masonic Cancer Center, University of Minnesota
Data source: Masonic Cancer Center, University of Minnesota

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations